截至月份: 2026年1月31日 狀態: 新提交 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 公司名稱: 科笛集团 (於開曼群島註冊成立的有限公司) 呈交日期: 2026年2月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02487 | 說明 普通股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,500,000,000 USD | | 0.00002 USD | | 50,000 | | 增加 / 減少 (-) | | | 0 | | USD | | | | 本月底結存 | | | 2,500,000,000 USD | | 0.00002 USD | | 50,000 | 致：香港交易及結算所有限公司 本月底法定/註冊股本總額： USD 50,000 第 1 頁 ...

此前科笛-B发布公告，本集团CU-20101(注射用A型肉毒毒素)用于改善中度至重度眉间纹的中国III期临 床试验(该临床试验)取得积极的顶线结果。 香港联交所最新资料显示，1月26日，科笛-B(02487)股东将股票由花旗银行转入摩根士丹利香港证券， 转仓市值1.22亿港元，占比7.07%。 ...

此前科笛-B发布公告，本集团CU-20101(注射用A型肉毒毒素)用于改善中度至重度眉间纹的中国III期临 床试验(该临床试验)取得积极的顶线结果。 智通财经APP获悉，香港联交所最新资料显示，1月26日，科笛-B(02487)股东将股票由花旗银行转入摩 根士丹利香港证券，转仓市值1.22亿港元，占比7.07%。 ...

Market Performance - The Hong Kong stock market experienced a decline, with the Hang Seng Index falling by 0.29% to 26,487.51 points, the Hang Seng Tech Index down 1.16% to 5,683.44 points, and the National Enterprises Index decreasing by 0.43% to 9,094.76 points [1] - Major technology stocks generally declined, with Alibaba down 0.44%, Tencent down 1.48%, and Xiaomi down 2.74%, while JD.com saw a slight increase of 0.09% [1] - New consumption concept stocks performed well, with Pop Mart rising by 9% and Naixue's Tea increasing by over 4% [1] Corporate News - Codex-B (02487.HK) reported positive top-line results from a Phase III clinical trial for CU-20101, an injectable botulinum toxin type A for moderate to severe glabellar lines [2] - Saint Bella (02508.HK) entered a strategic cooperation framework agreement with Cloudwise Technology to explore the integration of AI and robotics in high-demand home care scenarios [2] Profit Forecasts - China Taiping (00966.HK) expects a net profit increase of approximately 215% to 225% in 2025, compared to 8.432 billion HKD in the previous year [3] - TCL Electronics (01070.HK) anticipates an adjusted net profit of approximately 2.33 billion to 2.57 billion HKD in 2025, representing a growth of 45% to 60% [3] - Jihong Co. (02603.HK) forecasts a net profit of approximately 273 million to 291 million RMB in 2025, a year-on-year increase of 50% to 60% [3] - Guolian Minsheng (01456.HK) expects a net profit of 2.008 billion RMB in 2025, a growth of around 406% [3] - China Railway (00390.HK) reported a new contract amount of 1,165.98 billion RMB in Q4 2025, with a cumulative new contract amount of 2,750.9 billion RMB, a year-on-year growth of 1.3% [3] Sales and Revenue - Shenzhen Holdings (00604.HK) anticipates a total contract sales amount of approximately 13.311 billion RMB in 2025, a decrease of 21.55% [4] - SF Holding (06936.HK) reported a total revenue of 27.339 billion RMB in December from its logistics, supply chain, and international businesses, reflecting a year-on-year growth of 3.41% [5] Institutional Insights - Dongwu Securities noted that the Hong Kong market is in a long-term upward trend but faces short-term challenges, with strong consensus on domestic fundamentals but mixed views on overseas factors [9] - Huaxia Fund emphasized the high sensitivity of the Hong Kong market to corporate earnings and macroeconomic data, suggesting that positive economic surprises could significantly boost market expectations [10] - Tianfeng Securities highlighted that the Hong Kong market has the foundation for a rebound due to valuation recovery and sentiment improvement, but upward momentum may be constrained by high overseas interest rates [10] - Huaxi Securities pointed out that the "AI+" logic is catalyzing valuation optimization in the Hong Kong market, with a focus on internet, technology, and emerging consumption sectors [10]

Core Viewpoint - After a cumulative decline of 35.88% in stock price in 2025, the company Kedi-B (02487) has not yet found a way to reverse this downward trend in 2026, despite a year-to-date increase of over 7% as of January 19, 2026, primarily due to a low base from the previous year's closing price [1]. Group 1: Stock Performance - The stock price of Kedi-B experienced a significant drop of 5.02% on the last trading day of 2025, closing at 4.54 HKD, which contributed to the favorable year-to-date performance in 2026 [1]. - The stock price remains in a downward trend, with fluctuations indicating ongoing volatility rather than a recovery [1]. - Following the announcement of positive results from the Phase III clinical trial of CU-20101, the stock saw a temporary increase, suggesting potential stabilization [1][10]. Group 2: Market Dynamics - After being removed from the Hong Kong Stock Connect list in March 2025, Kedi-B's stock price fell to a low of 3.64 HKD within a month, but rebounded significantly after the release of its annual report in April 2025, which showcased strong fundamentals [2]. - The stock's performance is influenced by the behavior of Hong Kong Stock Connect funds, which typically engage in left-side trading strategies, leading to a rapid sell-off following the removal from the list [2]. - The holding ratio of Hong Kong Stock Connect funds decreased from 10.09% to 2.29% over several months, indicating a significant outflow of capital [3]. Group 3: Financial Performance - Kedi-B's 2024 annual report revealed a total revenue increase of approximately 103% year-on-year, with gross profit rising by about 102%, and a reduction in net loss by 77.91% [7]. - The revenue growth was attributed to increased sales of hair loss and skincare products, along with improved gross margins from the skincare brand line [7]. - The company announced plans to issue 28.9 million shares at a price of 8.40 HKD each to raise approximately 240 million HKD, with 45% of the funds allocated for the commercialization of new products [8]. Group 4: Product Development - The company is focusing on the commercialization of CU-40102 and CU-10201, with market expectations for CU-40102 to potentially exceed 1 billion HKD in its first full year, and CU-10201 estimated at 50 million HKD [9]. - CU-20101 has shown promising results in clinical trials, demonstrating efficacy comparable to BOTOX and a favorable safety profile, which could enhance its market potential [13][14]. - The competitive landscape for botulinum toxin products in China includes established players with significant market shares, posing challenges for Kedi-B as a new entrant [14].

Core Viewpoint - The stock price of Kedi-B (02487) has declined by 35.88% in 2025 and has not yet found a way to rebound in 2026, despite a year-to-date increase of over 7% as of January 19, 2026, primarily due to a low base from a significant drop at the end of 2025 [1] Group 1: Stock Performance and Market Reactions - Kedi's stock price experienced a significant drop of 5.02% on the last trading day of 2025, closing at 4.54 HKD, which contributed to the favorable year-to-date performance in 2026 [1] - The announcement of positive Phase III clinical trial results for CU-20101 (injectable type A botulinum toxin) on January 19, 2026, led to a temporary increase in stock price, indicating potential stabilization [1] - Following its removal from the Hong Kong Stock Connect list in March 2025, Kedi's stock price fell to a low of 3.64 HKD, but rebounded significantly after the release of its annual report in April 2025, showcasing strong fundamentals [2] Group 2: Shareholding and Liquidity Issues - After being removed from the Stock Connect, Kedi's shareholding by Stock Connect funds decreased from 10.09% to 2.29% by January 16, 2026, indicating a significant outflow of funds [2][3] - The accelerated outflow of Stock Connect funds has reduced selling pressure but has also led to a noticeable decline in liquidity for Kedi [5] - Kedi's trading volume has significantly decreased, with only four trading days exceeding 1 million shares in the past four and a half months, contrasting sharply with the previous year's performance [5] Group 3: Financial Performance and Future Prospects - Kedi's revenue for the first half of 2025 decreased by 30.6% to approximately 66.3 million HKD, with a net loss of about 239 million HKD, reflecting challenges due to strategic changes and the termination of a partnership with a U.S. skincare brand [8] - The company plans to issue 28.9 million shares at a price of 8.40 HKD each to raise approximately 240 million HKD, with 45% of the proceeds allocated for the commercialization of new products CU-40102 and CU-10201 [8] - Market forecasts suggest that CU-40102 could generate over 100 million HKD in its first full year, with peak sales potential estimated between 1 billion to 2 billion HKD, while CU-10201 is expected to reach 50 million HKD with peak sales of 500 million to 1 billion HKD [9] Group 4: Clinical Trial Results and Competitive Landscape - The clinical trial results for CU-20101 showed efficacy comparable to BOTOX®, meeting non-inferiority standards, and demonstrated good safety profiles without serious adverse events [12] - The competitive landscape for botulinum toxin products in China includes established players like Allergan's BOTOX® and Lanzhou Biological's Hengli, which dominate the market, making Kedi's entry into this space uncertain [13]

Core Viewpoint - The company has announced positive topline results from the Phase III clinical trial of CU-20101, an injectable botulinum toxin type A, for the treatment of moderate to severe glabellar lines in China [1][2] Group 1: Clinical Trial Results - The clinical trial consists of two phases: a randomized, multicenter, double-blind, positive-controlled trial followed by an open-label trial to assess the efficacy and safety of CU-20101 [1] - The trial compared CU-20101 to the reference product BOTOX, with results indicating that CU-20101 met non-inferiority standards for treatment success rates based on both investigator and participant assessments [1] - Safety results showed that CU-20101 had a good overall safety profile, with no adverse events leading to trial withdrawal or death, and no new safety signals compared to BOTOX [1] Group 2: Production and Market Potential - CU-20101 will be produced without the use of animal-derived materials, reducing the risk of transmissible spongiform encephalopathy (TSE) infections and related allergic reactions, which is expected to enhance its safety profile [2] - The introduction of CU-20101 is anticipated to enrich the company's skin product portfolio and create synergies with existing products, addressing the broad demand in the skin treatment market [2] - The diversified product layout is expected to help the company capture a larger market share in the skin treatment sector [2]

Core Viewpoint - The clinical trial results for CU-20101, an injectable botulinum toxin type A for treating moderate to severe glabellar lines, have shown positive outcomes, indicating its efficacy and safety comparable to BOTOX® [1][2] Group 1: Clinical Trial Results - The clinical trial for CU-20101 is a two-phase study, with the first phase being a randomized, multi-center, double-blind, positive drug-controlled trial, and the second phase being an open-label trial [1] - The trial is set to complete all subject exits by November 2025 and database lock by early January 2026 [1] - Efficacy results indicate that CU-20101 meets non-inferiority standards compared to BOTOX®, with success rates supported by both investigator assessments and independent evaluations [1] Group 2: Safety Profile - CU-20101 demonstrated good overall safety, with no adverse events leading to trial withdrawal or death, and no serious adverse events related to treatment [1] - The safety profile of CU-20101 is comparable to that of BOTOX®, with no new safety signals reported [1] Group 3: Production and Market Potential - CU-20101 will be produced without animal-derived materials, reducing the risk of transmissible spongiform encephalopathy (TSE) infections and related allergic reactions, which is expected to enhance its safety profile [2] - The introduction of CU-20101 will diversify the company's skin product portfolio and create synergies with existing products, potentially increasing market share in the skin treatment market [2]

Core Viewpoint - The company Codex-B (02487.HK) announced positive topline results from its Phase III clinical trial for CU-20101 (injectable type A botulinum toxin) aimed at improving moderate to severe glabellar lines in China [1] Group 1: Clinical Trial Details - The clinical trial is a two-phase study, with the first phase being a randomized, multi-center, double-blind, positive drug-controlled trial [1] - The second phase is an open-label clinical trial designed to evaluate the efficacy and safety of CU-20101 [1] - The trial uses the reference product Botox® (injectable type A botulinum toxin) as a control [1] Group 2: Timeline - The clinical trial is expected to complete enrollment of all subjects by November 2025 [1] - Database lock is anticipated to be completed in early January 2026 [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Cutia Therapeutics 科笛集團 （於開曼群島註冊成立之有限公司） （股份代號：2487） 1 CU-20101在生產工藝過程中將不使用動物源性材料，從而消除傳染性海綿狀腦病 (TSE)感染和相關過敏反應風險，預計將具有良好的安全性優勢。CU-20101將進 一步豐富本集團的皮膚產品矩陣，並有利於與本集團現有產品形成協同效應。面 向皮膚治療市場廣泛的需求，多元化產品的佈局將有望為本集團取得更大的市場 份額。 自願公告 CU-20101（注射用A型肉毒毒素）用於改善中度至重度眉間紋的 中國III期臨床試驗取得積極的頂線結果 本公告由科笛集團（「本公司」，連同其附屬公司統稱「本集團」）自願刊發，以告知 本公司股東及潛在投資者有關本集團最新業務發展資料。 本公司董事會（「董事會」）欣然宣佈，本集團CU-20101（注射用A型肉毒毒素）用 於改善中度至重度眉間紋的中國III期臨床試驗（「該臨床試驗 ...